Arcellx, Inc. ( ACLX ) NASDAQ Global Select

Cena: 71.23 ( -0.75% )

Aktualizacja 08-22 21:58
NASDAQ Global Select
Branża: Biotechnology
Finanse
Rachunek zysków i strat
Bilans
Przepływy pieniężne
Prognozy
Statystyki
Dywidendy
Rekomendacje
Modele wyceny
Wskaźniki
Analiza techniczna

Notowania:

Opis firmy:

Arcellx, Inc., firma biotechnologiczna na stadium klinicznym, angażuje się w rozwój różnych immunoterapii u pacjentów z rakiem i innymi nieuleczalnymi chorobami. Głównym kandydatem do produktu DDCAR firmy jest CART-DBCMA, który jest w badaniu klinicznym fazy 1 w leczeniu pacjentów z nawrotowym lub opornym (R/R) szpiczakiem mnogim (MM). Opracowuje również ACLX-001, kombinację immunoterapeutyczną złożoną z komórek ARC-T i dwugalertych białek Sparx ukierunkowanych na BCMA do leczenia R/R mm; ACLX-002 i ACLX-003 do leczenia ostrej białaczki szpikowej R/R (AML) i zespołu mielodysplastycznego (MDS); oraz inni kandydaci na produkty AML/MDS, a także programy guzów stałych. Firma była wcześniej znana jako Encarta Therapeutics, Inc. i zmieniła nazwę na Arcellx, Inc. w styczniu 2016 r. Arcellx, Inc. został zarejestrowany w 2014 roku i ma siedzibę w Gaithersburgu w stanie Maryland.

Informacje o spółce:
Sektor: Zdrowie
Branża: Biotechnology
Zatrudnienie: 130
Giełda: NASDAQ Global Select
Ilość akcji w obrocie: 70.7628
Ilość akcji: Brak danych
Debiut giełdowy: 2022-02-04
WWW: https://arcellx.com
CEO: Mr. Rami Elghandour
Adres: 25 West Watkins Mill Road
Siedziba: 20878 Gaithersburg
ISIN: US03940C1009
Wskaźniki finansowe
Kapitalizacja (USD) 3 950 338 159
Aktywa: 764 909 000
Cena: 71.23
Wskaźnik Altman Z-Score: 9.3
Stabilny (niskie ryzyko bankructwa)
Dywidenda: 0
P/E: -20.9
Ilość akcji w obrocie: 71%
Średni wolumen: 531 422
Ilość akcji 55 458 910
Wskaźniki finansowe
Przychody TTM 155 818 000
Zobowiązania: 281 891 000
Przedział 52 tyg.: 47.86 - 107.37
Piotroski F-Score: 6
Umiarkowany (średnia jakość finansowa)
EPS: -3.4
P/E branży: 28.3
Beta: 0.265
Raport okresowy: 2025-11-06
WWW: https://arcellx.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. Rami Elghandour Chairman of the Board, Chief Executive Officer & President 941 670 1979
Dr. Christopher R. Heery M.D. Chief Medical Officer 683 400 1980
Ms. Michelle Lim Gilson Chief Financial Officer 602 796 1993
Mr. Neeraj P. Teotia Chief Commercial Officer 461 949 1975
Ms. Kate Aiken Chief People Officer 0 0
Mr. David Tice Ph.D. Chief Scientific Officer 0 1971
Ms. Maryam Abdul-Kareem J.D., M.S. General Counsel & Chief Legal Officer 0 0
Ms. Myesha Lacy Chief Investor & Communications Officer 0 0
Ms. Aileen Fernandes Chief Business Officer 0 0
Mr. Narinderjeet Singh M.S. Chief Technical Officer 0 1972
Lista ETF z ekspozycją na akcje Arcellx, Inc.
Symbol ETF Ilość akcji Wartość
IWM 882 242 62 983 243
XBI 684 427 47 827 502
VB 672 863 44 308 028
VBK 378 254 24 908 025
IWO 323 701 23 108 993
IBB 241 985 17 275 336
SCHA 187 042 13 242 007
VTWO 186 435 12 276 744
XWEH.DE 164 445 10 280 467
XMWD.L 164 445 11 739 714
DBXW.DE 164 445 10 280 467
VHT 103 057 6 786 303
XS5E.DE 88 511 5 533 347
XSPX.L 88 511 478 830 109
XSPU.L 88 511 6 318 770
XSXD.L 88 511 6 318 770
XS5G.L 88 511 4 788 301
D5BM.DE 88 511 5 533 347
IDNA 66 688 4 770 859
LABU 64 073 4 574 171
R2SC.L 55 065 2 985 200
R2US.L 55 065 3 939 350
ZPRR.DE 55 065 3 449 688
DRDR.L 51 314 2 772 661
2B78.DE 51 314 3 204 634
HEAL.L 51 314 3 663 277
ITOT 47 090 3 361 736
SMLF 43 452 3 102 045
DFAC 35 382 2 525 920
BTEE.L 32 855 2 345 510
2B70.DE 32 855 2 051 852
BTEC.L 32 855 2 345 510
BTEK.L 32 855 1 775 269
VTWG 32 442 2 136 305
CANC 30 737 2 198 924
FSMD 29 185 2 060 169
SBIO 26 300 1 877 557
SCHB 24 283 1 730 663
2B77.DE 23 288 1 454 370
AGED.L 23 288 1 662 518
AGES.L 23 288 1 258 326
XRS2.DE 21 805 1 363 148
XRSU.L 21 805 1 556 638
XRSG.L 21 805 117 960 536
RSSL 18 718 1 336 278
FESM 17 238 1 216 830
JPSE 16 248 1 159 944
ESML 14 922 1 067 519
ONEQ 13 919 982 542
FHLC 13 852 977 812
BBSC 13 570 968 762
IWV 10 794 770 557
ISCG 10 363 739 795
TECB 8 862 632 628
PRFZ 8 198 586 484
ESGV 7 919 521 466
SXRG.DE 7 431 464 054
CUSS.L 7 431 530 469
CUS1.L 7 431 401 501
CSUSS.MI 7 431 464 054
XSU.TO 6 332 625 567
DFAU 6 006 428 768
GSSC 5 757 397 233
XCHA.L 4 250 303 401
XCHA.DE 4 250 265 688
EZM 4 143 295 768
UWM 3 705 264 499
URTY 3 067 218 953
VTHR 2 850 187 672
FMED 2 661 187 839
BIB 2 030 144 921
IBBQ 2 009 143 723
DCOR 1 940 138 496
BBC 1 829 129 109
ISCB 1 741 124 264
STXK 1 647 117 579
TILT 1 057 75 459
XUU.TO 852 84 171
V3AL.L 448 29 500
V3AB.L 448 22 355
V3AA.L 448 29 500
WDNA.L 414 26 226
WBIO.L 414 26 226
ZPRV.DE 327 17 844
USSC.L 327 20 377
BMED 282 20 102
XBAL.TO 271 26 809
USFM.L 237 16 961
USUE.DE 237 16 961
WDNA 202 14 420
CBUG.DE 154 9 637
EWSA.AS 154 11 017
XUH.TO 126 8 997
HDG 44 3 141
AVIE 43 3 076
XTR.TO 5 364
SC0K.DE 0 217 357
PZW.TO 0 2 742
SBIO.L 0 1 152 923
RTYS.L 0 248 068
SBIO.MI 0 1 010 191
Wiadomości dla Arcellx, Inc.
Tytuł Treść Źródło Aktualizacja Link
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced new positive data from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel), in patients with relapsed or refractory multiple myeloma (RRMM). These data will be presented during an oral presentation at the EHA2025 Congress in Milan. businesswire.com 2025-05-14 13:30:00 Czytaj oryginał (ang.)
Arcellx, Inc. (ACLX) Reports Q1 Loss, Lags Revenue Estimates Arcellx, Inc. (ACLX) came out with a quarterly loss of $1.13 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.14 per share a year ago. zacks.com 2025-05-08 22:10:41 Czytaj oryginał (ang.)
Baron Health Care Fund Q1 2025 Top Net Purchases And Sales Initiated positions in Waters Corporation, Penumbra, McKesson, Masimo, and added to UnitedHealth Group due to strong market positions and growth potential. Waters Corporation's growth driven by biopharmaceutical quality control, new regulations, and product replacement cycles, targeting high single to low double-digit revenue growth. Penumbra's mechanical thrombectomy devices target underpenetrated markets with potential FDA approval for Thunderbolt device as a growth catalyst. seekingalpha.com 2025-04-29 15:45:00 Czytaj oryginał (ang.)
Baron Health Care Fund Q1 2025 Top Contributors And Detractors Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals saw increased investor confidence in its cystic fibrosis franchise and evolving pipeline, including promising non-opioid pain treatments and kidney disease drugs. UnitedHealth Group's shares gained as 2024 headwinds subsided, Medicare Advantage rates improved, and higher-margin Optum segments grew, insulating it from tariff impacts. seekingalpha.com 2025-04-29 15:30:00 Czytaj oryginał (ang.)
Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointments of Andrew Galligan and Kristin Myers to its Board of Directors. Mr. Galligan is a proven financial executive who brings over three decades of strategic leadership experience to the Arcellx Board. Ms. Myers, a highly experienced healthcare. businesswire.com 2025-03-20 18:00:00 Czytaj oryginał (ang.)
Arcellx CMO Discusses Novel Investigational CAR-T Therapy During Multiple Myeloma Awareness Month NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Today's Marketplace (TMP) is proud to announce a featured interview with Arcellx, Inc. (NASDAQ: ACLX) Chief Medical Officer Christopher Heery, M.D., and Jessica Clark, DNP, RN, Dean of the College of Nursing at Creighton University. globenewswire.com 2025-03-18 10:44:00 Czytaj oryginał (ang.)
Arcellx Impressive Safety Data Leaves Doubts Arcellx's innovative cell therapy platform shows promising potential in treating multiple myeloma, a significant unmet medical need. Strong clinical trial results and strategic partnerships bolster confidence in Arcellx's growth trajectory and market position. Clarity is needed around mechanistic differentiation on D-Domain safety results before fully buying into the story. seekingalpha.com 2025-03-17 13:27:43 Czytaj oryginał (ang.)
Arcellx, Inc. (ACLX) Reports Q4 Loss, Lags Revenue Estimates Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.87 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to earnings of $0.42 per share a year ago. zacks.com 2025-02-27 22:05:21 Czytaj oryginał (ang.)
Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, at 1:10 p.m. ET. A live webcast of this discussion will be accessible from Arcellx's website at www.arcellx.com in the Investors s. businesswire.com 2025-02-26 18:00:00 Czytaj oryginał (ang.)
5 Biotech Breakthrough Stocks to Watch in 2025 After a decent first half, the drug and biotech sector saw a major downturn in the second half due to disappointing third-quarter sales and profits, guidance cuts, pipeline setbacks and the appointment of Robert F. Kennedy Jr., a vaccine skeptic, as the head of Health and Human Services. zacks.com 2024-12-23 12:40:34 Czytaj oryginał (ang.)
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead. Arcellx stock reversed lower Monday on positive results for its rival to Legend Biotech's multiple myeloma treatment, Carvykti. The post Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. investors.com 2024-12-09 12:50:35 Czytaj oryginał (ang.)
Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients On Sunday, Arcellx, Inc.  ACLX revealed new data from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma (RRMM). benzinga.com 2024-12-09 09:50:13 Czytaj oryginał (ang.)
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced new positive data from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel (anito-cel), in patients with relapsed or refractory multiple myeloma (RRMM). These data will be presented during an oral presentation at the 66th American Society of. businesswire.com 2024-12-09 01:00:00 Czytaj oryginał (ang.)
Are You Looking for a Top Momentum Pick? Why Arcellx, Inc. (ACLX) is a Great Choice Does Arcellx, Inc. (ACLX) have what it takes to be a top stock pick for momentum investors? Let's find out. zacks.com 2024-11-13 15:06:11 Czytaj oryginał (ang.)
Is Arcellx (ACLX) Outperforming Other Medical Stocks This Year? Here is how Arcellx, Inc. (ACLX) and AbbVie (ABBV) have performed compared to their sector so far this year. zacks.com 2024-11-08 12:46:48 Czytaj oryginał (ang.)
Arcellx, Inc. (ACLX) Reports Q3 Loss, Lags Revenue Estimates Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.81 per share a year ago. zacks.com 2024-11-07 20:15:29 Czytaj oryginał (ang.)
Arcellx (ACLX) Stock Jumps 6.7%: Will It Continue to Soar? Arcellx (ACLX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. zacks.com 2024-11-07 09:31:12 Czytaj oryginał (ang.)
Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma Arcellx leverages proprietary platforms like D-Domain, ddCAR, and ARC-SparX to enhance immune response, targeting multiple myeloma, AML, MDS, and solid tumors. ACLX's lead therapy, anito-cel, shows strong clinical results in relapsed/refractory multiple myeloma, even for high-risk patients. Arcellx's strategic partnership with Kite Pharma validates its technology, potentially leading to milestone payments of up to $935 million. seekingalpha.com 2024-09-10 12:30:00 Czytaj oryginał (ang.)
Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.50 per share a year ago. zacks.com 2024-08-08 22:25:34 Czytaj oryginał (ang.)
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals The biotech industry has fallen on hard times over the last few years, no thanks to venture capital drying up, tighter regulatory conditions and the harsh reality of the post-pandemic healthcare environment. As a result, biotech breakthrough stocks fell out of favor with investors and were among the worst performers in the stock market. investorplace.com 2024-07-04 18:13:23 Czytaj oryginał (ang.)